Immunome (NASDAQ:IMNM) Hits New 1-Year High – Here’s What Happened

Immunome, Inc. (NASDAQ:IMNM) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $20.65 and last traded at $20.54, with a volume of 118976 shares. The stock had previously closed at $20.30.

Analyst Ratings Changes

A number of research analysts recently issued reports on IMNM shares. Wedbush restated an “outperform” rating and set a $21.00 price objective on shares of Immunome in a research report on Friday, November 7th. The Goldman Sachs Group assumed coverage on shares of Immunome in a report on Monday, September 22nd. They set a “buy” rating and a $26.00 price target for the company. Stephens increased their price objective on shares of Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a report on Monday, November 17th. Evercore ISI began coverage on shares of Immunome in a research report on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Truist Financial initiated coverage on shares of Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Immunome Stock Performance

The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -6.63 and a beta of 2.17. The company’s 50 day simple moving average is $16.94 and its 200 day simple moving average is $12.24.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.

Institutional Trading of Immunome

A number of hedge funds and other institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its stake in Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after buying an additional 2,054,640 shares in the last quarter. Redmile Group LLC lifted its holdings in Immunome by 11.0% in the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock valued at $36,081,000 after acquiring an additional 533,161 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Immunome by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock valued at $57,304,000 after purchasing an additional 368,674 shares in the last quarter. EcoR1 Capital LLC grew its stake in shares of Immunome by 5.2% in the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock worth $27,454,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Immunome by 6.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after purchasing an additional 117,523 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.